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PERSPECTIVE
Resistance to antimicrobial agents is an emerging 
problem worldwide. Awareness of the undesirable conse-
quences of its widespread occurrence has led to the initia-
tion of antimicrobial agent resistance monitoring programs 
in several countries. In 1995, Denmark was the ﬁ  rst country 
to establish a systematic and continuous monitoring pro-
gram of antimicrobial drug consumption and antimicrobial 
agent resistance in animals, food, and humans, the Dan-
ish Integrated Antimicrobial Resistance Monitoring and 
Research Program (DANMAP). Monitoring of antimicrobial 
drug resistance and a range of research activities related 
to DANMAP have contributed to restrictions or bans of use 
of several antimicrobial agents in food animals in Denmark 
and other European Union countries. 
I
n 1969, the Swann Committee recommended to the Brit-
ish government that antimicrobial agents used for hu-
man therapy, or antimicrobial substances that selected for 
resistance to these agents, should not be used for growth 
promotion in food animals (1). In 1993, the ﬁ  rst report of 
nonhospital and nonhuman reservoirs of vanA vancomy-
cin-resistant Enterococcus faecium (VREF) in the United 
Kingdom was published (2). This ﬁ  nding was surprising 
because no therapeutic glycopeptide (vancomycin or teico-
planin) had been used in food animals. However, another 
glycopeptide, avoparcin, had been used for decades as a 
feed additive for growth promotion; it was suggested that 
the occurrence of VREF might be related to this usage. 
The ﬁ  nding of VREF in the United Kingdom led to simi-
lar investigations and subsequent ﬁ  ndings in Germany and 
Denmark in 1994 and 1995 (3,4). In 1995, one of the only 
antimicrobial agents available for treatment of multidrug-
resistant enterococci and methicillin-resistant Staphylococ-
cus aureus (MRSA) infections was vancomycin. On May 
18, 1995, the Danish Minister of Agriculture and Fisheries 
banned the use of avoparcin nationally because new scien-
tiﬁ  c evidence showed that avoparcin used as a growth pro-
moter in food animals constituted a potential threat to hu-
man health (Article 11 of Council Directive 84/587/EEC). 
In July 1995, the ban became effective in all countries in 
the European Union (EU) after a decision by the EU Coun-
cil of Ministers. 
The avoparcin ban called attention to the wide array 
of antimicrobial substances being used in food animals 
for growth promotion or disease control and to the risk 
for transfer of other resistant bacteria or resistance genes 
from animals to humans through the food chain. A system-
atic approach was needed to generate the data necessary 
to determine the magnitude of current or potential future 
public health hazards from nonhuman use of antimicrobial 
agents. In September 1995, the Danish Integrated Anti-
microbial Resistance Monitoring and Research Program 
(DANMAP) was established at the initiative of the Dan-
ish Ministry of Health and the Danish Ministry of Food, 
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Agriculture and Fisheries, as a coordinated national moni-
toring and research program. Participants in the program 
are Statens Serum Institut, the National Food Institute and 
National Veterinary Institute at the Technical University of 
Denmark, the Danish Veterinary and Food Administration, 
and the Danish Medicines Agency. DANMAP has 4 objec-
tives: 1) monitor the consumption of antimicrobial agents 
for food animals and humans; 2) monitor the occurrence 
of antimicrobial agent resistance in bacteria isolated from 
food animals, food of animal origin, and humans; 3) study 
associations between antimicrobial agent consumption and 
antimicrobial agent resistance; and 4) identify routes of 
transmission and areas for further research.
Denmark was the ﬁ  rst country to establish systematic 
and continuous monitoring of antimicrobial agent con-
sumption and resistance in animals, food, and humans. 
Other antimicrobial agent resistance monitoring programs 
are now established in other countries: Norway (Usage of 
Antimicrobial Agents and Occurrence of Antimicrobial 
Resistance in Norway [NORM/NORM-VET]) (5), Sweden 
(Swedish Veterinary Antimicrobial Resistance Monitoring 
[SVARM] and  Report on Swedish Antibiotic Utilisation 
and Resistance in Human Medicine [SWEDRES])(6), the 
Netherlands (Monitoring of Antimicrobial Resistance and 
Antibiotic Usage in Animals in the Netherlands [MARAN] 
and Consumption of Antimicrobial Agents and Antimicro-
bial Resistance among Medically Important Bacteria in the 
Netherlands  [NETHMAP]) (7,8), Canada (Canadian Inte-
grated Program for Antimicrobial Resistance Surveillance   
[CIPARS]) (9), and the United States (National Antimicro-
bial Resistance Monitoring System. [NARMS]) (10). 
The ﬁ  rst results covering all 3 reservoirs from DAN-
MAP were published in 1997 (11); annual reports have 
subsequently been published (www.danmap.org). We 
present selected results and experiences from 11 years of 
monitoring and reporting of antimicrobial agent consump-
tion and antimicrobial agent resistance in bacteria isolated 
from animals, food, and humans in Denmark.
Description
DANMAP collects and presents data on consumption 
of antimicrobial agents and the occurrence of resistance in 
indicator bacteria, zoonotic bacteria, and pathogenic bacteria 
from animals, food, and humans. The setup for sampling of 
isolates and data for DANMAP are brieﬂ  y described below. 
A schematic description of sampling of isolates and data ﬂ  ow 
is presented in Figure 1. A more detailed description can be 
found in the DANMAP reports (www.danmap.org).
Isolates from Animals
Bacterial isolates are collected from healthy animals 
at slaughter (Escherichia coli, enterococci, and Campylo-
bacter spp.) as well as from diagnostic submissions (Staph-
ylococcus hyicus from pigs and E. coli from cattle and pigs 
with diarrhea). Salmonella isolates from subclinical as well 
as clinical cases of salmonellosis are included. Salmonella 
isolates from subclinically infected pigs and poultry are 
collected on farms as part of a national Salmonella moni-
toring program.
Isolates from Food
All food samples are collected at wholesale and retail 
outlets during routine inspections by the Regional Veteri-
nary and Food Control Authorities (Salmonella and Cam-
pylobacter spp.) or on request from DANMAP (enterococci 
and E. coli). Bacterial isolates included in the monitoring 
program originate from food from Denmark as well as im-
ported food.
Isolates from Healthy Persons in the Community
To monitor the level of resistance among healthy per-
sons, ongoing surveillance was initiated in 2002. Current-
ly, 1 isolate each of E. faecium, E. faecalis, and E. coli is 
sampled from each fecal sample, if isolated. Furthermore, 
a selective method is used to detect vancomycin-resistant 
enterococci.
Isolates from Patients in the Community 
and in Hospitals
Isolates of Salmonella and Campylobacter included in 
the monitoring program originate from diagnostic submis-
sions sent to Statens Serum Institut (SSI). For S. aureus 
testing, all blood isolates from 15 of 16 Danish counties 
and all MRSA isolates nationwide are sent to SSI. For 
Streptococcus pneumoniae testing, all isolates from blood 
and spinal ﬂ  uid found nationwide by clinical microbiology 
laboratories are sent to SSI. For E. coli, coagulase-nega-
tive staphylococci, and Streptococcus pyogenes, data on 
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Figure 1. Data ﬂ   ow. DANMAP, Danish Integrated Antimicrobial 
Resistance Monitoring and Research Program; DTU, Technical 
University of Denmark.  PERSPECTIVE
all isolates from blood samples (E. coli, coagulase-nega-
tive staphylococci), urine samples (E. coli), and clinical 
samples (S. pyogenes) submitted for susceptibility testing 
are provided by clinical microbiology laboratories partici-
pating in the Danish Study Group for Antimicrobial Resis-
tance Surveillance.
Changes after 11 Years of DANMAP
Ban of Antimicrobial Growth Promoters
In 1994, the consumption of antimicrobial growth pro-
moters constituted more than half of the total antimicrobial 
consumption by animals in Denmark (Figure 2). Antimi-
crobial growth promoters were used as an in-feed supple-
ment for nearly all broiler chicken and pig farms in Den-
mark. At the time avoparcin was banned, a high level of 
resistance to several antimicrobial growth promoters was 
observed among bacteria from production animals (11). 
Although use of avoparcin was banned in 1995, the total 
use of growth promoters increased until 1998. In the spring 
of 1998, the Danish pig and poultry producers voluntarily 
discontinued use of all antimicrobial growth promoters in 
ﬁ  nisher pigs and broiler chickens. DANMAP measured 
and documented the effect of this marked change in antimi-
crobial consumption in animal production.
By 2006, 11 years of monitoring data were available 
(Table; Figure 3) (12). The 1995 ban on avoparcin had a 
substantial effect on lowering the occurrence of VREF 
isolated from fecal samples from broiler chickens (Figure 
3). In 2005, <3% of the E. faecium isolates from broiler 
chickens were resistant to vancomycin (12). To avoid bias 
in the selection of the isolates, the VREF isolates included 
in DANMAP were detected by using a nonselective isola-
tion method. Although studies that used selective enrich-
ment for isolation of VREF have documented that VREF 
could still be isolated from a high percentage of poultry 
ﬂ  ocks several years after the ban of avoparcin (17,18), the 
quantity of VREF isolated from Danish poultry has been 
substantially reduced.
In contrast, no signiﬁ  cant change in the occurrence of 
VREF in pigs was observed in the ﬁ  rst years after the ban 
of avoparcin. Nearly all VREF isolated from pigs in Den-
mark belonged to the same clone; whereas VREF isolates 
from broilers were polyclonal (17,19). In the pig VREF 
clone, genes encoding resistance to glycopeptides (vanA) 
and macrolides (erm[B]) were shown to be located on the 
same mobile DNA element (19). The consumption of mac-
rolides (tylosin) for growth promotion decreased substan-
tially in 1998, and a statistically signiﬁ  cant decrease in the 
occurrence of VREF among E. faecium isolates from pigs 
was observed in 1999 and 2000, which suggests that per-
sistence of VREF among the pig population was caused by 
the continued use of macrolides, mainly tylosin, for growth 
promotion and therapy.
Since 2002, fecal samples from 485 healthy human 
volunteers in Denmark have been screened for vancomy-
cin-resistant enterococci. Only 3 VREF isolates (12,20) 
and 2 vancomycin-resistant E. faecalis isolates have been 
detected by using a selective isolation method (21).
Transfer of VREF from animals to humans can be 
difﬁ  cult to demonstrate, especially if only the vanA gene 
encoding vancomycin resistance is transferred. Several 
animal studies and 1 human study have shown that gene 
transfer between enterococcal isolates is possible in mouse 
and human intestines, which indicates that gene transfer 
can take place in intestines of humans that have eaten meat 
containing enterococci (22,23). Transfer of the vanA gene 
is cause for concern if it is transferred to an E. faecium 
isolate belonging to an invasive clone, e.g., clonal complex 
17, which causes E. faecium infections in humans (24).
In January 1998, another antimicrobial growth pro-
moter, virginiamycin, was banned from use in Denmark. 
Resistance to virginiamycin confers cross-resistance to 
pristinamycin and quinupristin/dalfopristin, a new anti-
microbial with a wide gram-positive spectrum including 
MRSA and VREF. The Danish ban on virginiamycin was 
based on the same concerns for human health as the ban 
on avoparcin. The ban on virginiamycin had an effect also 
on the occurrence of streptogramin-resistant E. faecium in 
broiler chickens and pigs (12).
In July 1999, virginiamycin, together with 3 other 
growth promoters—tylosin, spiramycin, and bacitracin—
was banned in the entire EU. The ﬁ  nal step in the termina-
tion of the use of antimicrobial agents for growth promo-
tion was taken in December 2002 when the EU Council 
of Ministers, with a Danish president, decided that all use 
of antimicrobial growth promoters should be terminated 
within the EU starting January 1, 2006 (25).
VetStat Monitoring Program
In Denmark, all antimicrobial agents used in animals, 
except coccidiostats used in poultry, are available by pre-
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Figure 2. Consumption of prescribed antimicrobial agents and 
growth promoters in animal production and prescribed antibacterial 
agents in humans, Denmark, 1990–2005 (12). DANMAP
scription only. To collect information about veterinary use 
of antimicrobial agents, the Danish Medicines Agency ob-
tained data from the pharmaceutical industry and importers 
during 1996–2001. These data were used in the ﬁ  rst DAN-
MAP reports (1996–2000). In addition, the consumption 
of antimicrobial agents from 1990 through 1994 was esti-
mated by data collected from the pharmaceutical industry. 
However, these data did not contain information on anti-
microbial agent use within the different animal species. On 
the basis of recommendations from the EU conference The 
Microbial Threat, held in Copenhagen in 1998, the Danish 
government decided that a monitoring system of all veteri-
nary use of prescription medicine on a detailed level should 
be developed (26). The implementation of this monitoring 
program, VetStat, was initiated in 2000. VetStat data on 
prescription medicines used in animals are collected from 
pharmacies, feed mills, and veterinary practitioners. From 
these 3 sources, detailed data comprising farm identity, 
species, age group, disease group, identity of medicine, 
amount, date of purchase, and identity of the prescribing 
veterinarian are obtained for all antimicrobial agents used 
in production animals. Valid data by animal species and 
age group level were reported for the ﬁ  rst time in the DAN-
MAP 2001 report.
Use of Fluoroquinolones in Animal Production
In 2002, the Danish regulation restricted the use of ﬂ  u-
oroquinolones, e.g., enroﬂ  oxacin, diﬂ  oxacin, and marbo-
ﬂ  oxacin, in animal husbandry. Fluoroquinolone use is legal 
in food animals only when susceptibility tests performed 
in an approved diagnostic laboratory show that the infect-
ing bacteria are resistant to all other antimicrobial agents 
registered for treatment in the animal species concerned 
(27). Subsequently, consumption of ﬂ  uoroquinolones for 
production animals (pigs, poultry, and cattle) was reduced 
from 114 kg in 2001 to 18 kg in 2005 (12).
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Table. DANMAP’s contributions to decreasing antimicrobial agent resistance in Denmark, 11 years* 
Sector Problem Intervention (reference) 
Type of 
intervention
Intervention had 
effect
High occurrence of vancomycin-
resistant Enterococcus faecium
isolates in food and production 
animals
Banned avoparcin: Denmark May 1995 and 
EU Dec 1997. Provided data for national and 
EU ban. Monitored effect of ban in animals, 
food, and healthy humans. 
Regulatory Yes 
High occurrence of streptogramin-
resistant E. faecium isolates in food 
and production animals 
Banned virginiamycin: Denmark Jan 1998  
and EU Jul 1999. Provided data for national 
and EU ban. Monitored effect of ban in 
animals, food, and healthy humans. 
Regulatory Yes 
High use of fluoroquinolones in 
animal production 
Restricted use of fluoroquinolones in animal 
husbandry, by Danish law in 2002. 
Regulatory Yes 
Food
animal
High use of antimicrobial agents in 
swine production 
Implemented new guidelines for veterinary 
practitioner prescription of antibacterial
agents for swine production in 2005. 
Guideline Not yet known 
Food Higher levels of resistance in 
Salmonella and Campylobacter
isolates from imported food than 
from Danish food 
Implemented evaluation of safety of food 
products, by November 2006. 
Regulatory Not  yet  known 
Increasing macrolide resistance in 
Streptococcus pneumoniae
Published report to prescribers in  
EPI-NEWS (13). 
Awareness 
campaign
Yes 
Increasing use of newer, broad-
spectrum antibiotics, especially in 
hospitals
Published report to prescribers in  
EPI-NEWS (14). 
Awareness 
campaign
No, use of newer, 
broad-spectrum 
antibiotics still 
increasing
Higher levels of resistance in travel-
associated Salmonella and 
Campylobacter infections 
Published report to prescribers in  
EPI-NEWS (14). 
Awareness 
campaign
Not yet known 
Increasing no. of methicillin-
resistant Staphylococcus aureus
(MRSA) cases 
Published report to prescribers in 
 EPI-NEWS (15). Informed national  
reference center, which reported to  
physicians and other prescribers (15). Made 
notification mandatory Nov 2006 (16).
Mandatory 
notification
Not yet known 
Increasing use of antimicrobial 
agents, outside and inside hospitals 
Published report to prescribers in  
EPI-NEWS (14). 
Awareness 
campaign
No, antibiotic use 
still increasing 
Human
Increasing ciprofloxacin resistance 
related to increasing ciprofloxacin 
use
Published report to prescribers in  
EPI-NEWS (14). 
Awareness 
campaign
No, ciprofloxacin 
use and resistance 
still increasing, but 
low compared with 
that of other 
countries
*DANMAP, Danish Integrated Antimicrobial Resistance Monitoring and Research Program; EU, European Union.  PERSPECTIVE
New Guidelines for Veterinary Prescription 
of Antimicrobial Agents for Pigs
Pigs constitute the largest volume of animals produced 
in Denmark. In 2005, a total of 25.7 millions pigs were pro-
duced, and pig production accounted for 82% of the total 
veterinary consumption of antimicrobial agents (12). From 
2002 through 2004, antimicrobial use increased by 27%; 
large regional differences indicated that the increase was 
related to local factors (27). To reduce the use of antimicro-
bial agents and encourage speciﬁ  c substitutions of differ-
ent agents in pig production, in 2005 the Danish Veterinary 
and Food Administration published a set of new guidelines 
for veterinary prescription of antimicrobial agents for pigs. 
The guidelines were developed in cooperation with rel-
evant national institutions. They exclude quinolones and 
cephalosporins from the list of recommended agents. The 
effect of these guidelines on antimicrobial agent use in pig 
production cannot yet be determined.
Increased Resistance in Zoonotic Bacteria 
from Imported Meat
Since 1998, levels of resistance have been higher in 
Salmonella isolates from imported food than in isolates 
from Danish food (28). In 2005, the occurrence of resis-
tance in Salmonella Typhimurium isolated from imported 
pork generally exceeded that of corresponding isolates 
from Denmark (12). A similar tendency was observed for 
Campylobacter jejuni isolated from poultry meat: imported 
poultry meat showed a higher resistance frequency than 
Danish poultry meat. The high frequency of antimicrobial 
agent resistance in Salmonella from imported pork and in 
Campylobacter spp. from imported poultry meat probably 
reﬂ  ects differences in the use of veterinary antimicrobial 
agents in the countries of origin as compared with Denmark 
(12). The higher occurrence of antimicrobial agent resis-
tance in zoonotic bacteria in imported meat products is im-
portant because a large part of meat consumed in Denmark 
is of foreign origin. In November 2006, case-by-case eval-
uation of the safety of imported meat was implemented.
In the DANMAP 2000 report, higher levels of resis-
tance in travel-associated Salmonella and Campylobacter 
infections were reported for the ﬁ  rst time (29). Increased 
ciproﬂ  oxacin resistance in isolates from infections acquired 
abroad was particularly signiﬁ  cant. Similarly, C. jejuni iso-
lates from human infections acquired abroad generally had 
a higher frequency of resistance to ciproﬂ  oxacin and tetra-
cycline (12). From 2001 through 2005, the number of long 
holidays (>4 overnight stays) for Danish travelers increased 
by 14%. The most popular destinations were Spain, France, 
and Italy, which accounted for >30% of the long holidays 
abroad in 2005. Travel to the southern part of Europe might 
be associated with risk of acquiring infections due to re-
sistant zoonotic pathogens because Salmonella and Cam-
pylobacter spp. isolated from meat produced in southern 
Europe are generally more resistant to antimicrobial agents 
than isolates obtained from meat produced in Denmark 
(30). Thereby, foodborne zoonotic infections acquired in 
southern Europe may offer limited therapeutic options. An-
other high-risk area for acquiring antimicrobial-resistant 
foodborne zoonotic infections is Asia (31).
Increased Human Consumption of 
Therapeutic Antimicrobial Agents
Since the early 1980s, data on use of antimicrobial 
agents for human therapy have been available from phar-
maceutical industry sources or from the Danish Medicines 
Agency. DANMAP systematically reports these data in 
conjunction with resistance data, which has enabled iden-
tiﬁ  cation of speciﬁ  c problems linked to antimicrobial con-
sumption for human therapy (Table).
Increasing use of antimicrobial agents by humans, 
both outside and inside hospitals, was reported by DAN-
MAP in 2000 (29). At the time, antimicrobial consump-
tion by outpatients was among the lowest in Europe and 
was similar to that in Germany, Sweden, and Austria (32). 
Since then the increase has continued for outpatients (data 
not shown) and hospitalized patients. The mean antimi-
crobial consumption in hospitals has increased by 39%, 
from 421 deﬁ  ned daily doses (DDD)/1,000 bed-days in 
1997 to 585 DDD/1,000 bed-days in 2004 (14). Much of 
this increase can be explained by increased hospital activ-
ity, i.e., an increased number of patients treated in hospitals 
concomitant with shorter lengths of hospital stay. Another 
reason for the increased consumption has been an increase 
in doses, based on better understanding of the pharmaco-
kinetic and pharmacodynamic properties of antimicrobial 
agents. Still, parts of the increase are unaccounted for, and 
much remains to be understood to explain this increase in 
antimicrobial consumption in humans and how it may be 
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Figure 3. Trends in glycopeptide resistance among Enterococcus 
faecium from broiler chickens and pigs and the consumption of 
the growth promoter avoparcin in animals, Denmark, 1994–2005 
(revised from 12).DANMAP
controlled. In addition to increased total use of antimicro-
bial agents, newer antimicrobial agents are being used, e.g., 
cephalosporins, ﬂ  uoroquinolones, and carbapenems, at the 
expense of extended-spectrum penicillins (except pivme-
cillinam), aminoglycosides, and macrolides (14). Although 
use of quinolones remains lower in Denmark than in Eu-
ropean countries (33), a small but statistically signiﬁ  cant 
increase in the frequency of ciproﬂ  oxacin-resistant E. coli 
isolates from urine has been observed since 2003 in pri-
mary healthcare facilities and in hospitals. The increase in 
ciproﬂ  oxacin resistance has occurred concurrently with a 
recent increase in the consumption of ﬂ  uoroquinolones, 
primarily ciproﬂ  oxacin (14,34).
Publication of MRSA Guidelines
An increase in MRSA cases was observed in 2000 
(97 cases) and continued in 2001 (104 cases) (29,35). The 
number of MRSA cases, including infection and coloniza-
tion, reached 856 in 2005 (12). As a response to this in-
crease, new national guidelines for the control and preven-
tion of MRSA were issued by the National Board of Health 
(35). The guidelines enforce use of the search-and-destroy 
policy in hospitals as well as in other healthcare institu-
tions such as nursing homes. Additionally, to maintain a 
low colonization pressure in Denmark and thus reduce 
cross-transmission, all MRSA-positive persons are offered 
eradication treatment (35). The guidelines also recommend 
that MRSA-positive persons be given a personal “MRSA 
card,” which must be shown at each contact with healthcare 
providers to ensure proper treatment and to prevent further 
transmission (35). To better monitor the new MRSA situa-
tion in Denmark and to facilitate implementation of control 
measures in connection with outbreaks, reporting MRSA 
cases has been mandatory since November 1, 2006 (16).
Increased Pneumococcal Resistance to Macrolides 
In 2000, susceptibility testing performed on pneumo-
coccal isolates from blood and cerebrospinal ﬂ  uid sent to 
SSI showed that the frequency of erythromycin resistance 
in pneumococci slowly increased from ≈0% in 1990 to 
3.4% in 1999 (36). This increase in macrolide resistance of 
pneumococci was probably related to a relative high con-
sumption of macrolides combined with a change in the dis-
tribution of the macrolides used (13). Since 2000, macro-
lide resistance in pneumococci from blood and spinal ﬂ  uid 
has been ≈5% (12).
The Danish experience shows that even if antimicro-
bial agent consumption is generally low and the frequency 
of resistance is correspondingly small, a temporary rise in 
consumption of even a single class of antimicrobial agent 
can shift this balance in an unfavorable direction. In Den-
mark, rational antimicrobial therapy is the tool to ensure 
optimum treatment of patients with bacterial infections and 
low levels of antimicrobial agent resistance. However, con-
tinuous training and efforts are essential to keep general 
practitioners as well as hospital specialists updated on the 
rational use of antimicrobial agents (14).
Possible New Areas for DANMAP Monitoring
Unlike the monitoring programs in Sweden and Nor-
way, DANMAP never included bacteria obtained from 
companion animals (5,6), and rational therapy guidelines 
for companion animals have not been promoted or imple-
mented in veterinary university clinics or private veterinary 
practices. Fluoroquinolone and cephalosporin consumption 
by companion animals in Denmark is substantial compared 
with that of food animals (37). Considering the shared en-
vironment of humans and companion animals, transfer of 
resistant bacteria or of mobile resistance determinants from 
companion animals to humans seems possible. Thus, emer-
gence of resistance to ﬂ  uoroquinolones and cephalosporins 
in companion animals should be a matter of concern and 
could be considered a new area for surveillance. Recently, 
MRSA has been detected in companion animals and in 
food-producing animals in other countries, the potential 
importance of which should also be monitored (38).
A substantial proportion of human Salmonella isolates 
belongs to serotypes other than S. Enteritidis and S. Ty-
phimurium. The occurrence of more uncommon serotypes 
is increasing and in 2005 represented ≈30% of all human 
Salmonella isolates (12). Prevalence of antimicrobial agent 
resistance varies greatly among less frequent Salmonella 
serotypes isolated in Denmark, and speciﬁ  c  serotypes 
showed a high level of resistance (39). These Salmonella 
serotypes, as well as other emerging or reemerging patho-
gens such as Mycobacterium tuberculosis (40), represent a 
potential focus area.
In future DANMAP reports, more attention should be 
given to the presence of extended-spectrum β-lactamase 
(ESBL)–producing E. coli and Salmonella from animals 
and humans. The emergence of ESBL resistance is a new 
threat for human therapy.
Conclusions
DANMAP has led to changes in the use of antimicro-
bial agents in Denmark and other countries. Until now, 
the effect in Denmark had been seen mostly in animals, 
but awareness has been raised for humans as well (Table). 
One of the strengths of DANMAP is cooperation between 
veterinary and human healthcare providers, thus offering 
a broad range of viewpoints and professionals. This inte-
grated program was made possible because access to all 
relevant data and samples that were already systematically 
collected from animals, food, and humans has been shared. 
To complete these data, a random sampling of indicator 
bacteria “from farm to fork” was implemented, which has 
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made follow-up of antimicrobial agent resistance for zoo-
notic and indicator bacteria possible.
The relationship between antimicrobial agent resis-
tance in the food supply and human foodborne infections 
is complex. It depends on the level of resistance of bacte-
ria in domestic food, level of resistance in imported food, 
and inﬂ  uence of travel abroad. The need for surveillance 
of antimicrobial consumption and resistance in animals 
and humans is universal because food, humans, and even 
livestock travel. Solid scientiﬁ  c data are needed for an evi-
dence-based debate and to facilitate further regulation re-
garding antimicrobial agent resistance and consumption.
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